NCT06943586NARecruiting

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

University of Alabama at Birmingham

Start Date

4/9/2025

Completion Date

4/1/2029

Summary

The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.

Detailed Description

This is a pilot clinical trial for feasibility

Eligibility Criteria

Age Range: 18 years to 89 years

Inclusion Criteria: * Patients 18-89 years of age * admitted to University of Alabama at Birmingham (UAB) main hospital with symptoms or signs of minor ischemic stroke, or high risk TIA * eligible to receive dual antiplatelet load (presented to the hospital within 66 hours of last known well) Exclusion Criteria: * diagnosis of atrial fibrillation, valvular heart disease, index stroke due to known hypercoagulability (subset of other determined etiology) or large vessel disease (culprit vessel stenosis of ≥50%) * prescribed anticoagulation prior to stroke * treated with intravenous thrombolysis * treated with mechanical thrombectomy * missing NIH Stroke Scale score

Interventions

GENETIC

CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

StrokeTransient Ischemic Attack (TIA)

Locations

University of Alabama at Birmingham

Birmingham, Alabama 35233

United States